Everything below concerns GHRH receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-22. Numbers and descriptions here follow the published literature rather than marketing material.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Collagen alpha-1(XXV) chain is a protein that in humans is encoded by the COL25A1 gene. COL25A1 is a brain-specific membrane-bound collagen. Proteolytic processing releases CLAC, a soluble form of COL25A1 containing the extracellular collagen domains that associates with senile plaques in Alzheimer disease (AD; MIM 104300) brains (Osada et al., 2005).[supplied by OMIM]
=== Proliferative phase === In the proliferative phase, immature granulation tissue containing plump, active fibroblasts forms. Fibroblasts quickly produce abundant type III collagen, which fills the defect left by an open wound. Granulation tissue moves, as a wave, from the border of the injury towards the center. As granulation tissue matures, the fibroblasts produce less collagen and become more spindly in appearance. They begin to produce the much stronger type I collagen. Some of the fibroblasts mature into myofibroblasts which contain the same type of actin found in smooth muscle, which enables them to contract and reduce the size of the wound.
Corneal cross-linking (CXL) with riboflavin (vitamin B2) and UV-A light is a surgical treatment for corneal ectasia such as keratoconus, PMD, and post-LASIK ectasia. It is used in an attempt to make the cornea stronger. According to a 2015 Cochrane review, there is insufficient evidence to determine if it is useful in keratoconus. In 2016, the US Food and Drug Administration approved riboflavin ophthalmic solution crosslinking based on three 12-month clinical trials.
Long bones are characterized by a shaft, the diaphysis, that is much longer than its width; and by an epiphysis, a rounded head at each end of the shaft. They are made up mostly of compact bone, with lesser amounts of marrow, located within the medullary cavity, and areas of spongy, cancellous bone at the ends of the bones. Most bones of the limbs, including those of the fingers and toes, are long bones. The exceptions are the eight carpal bones of the wrist, the seven articulating tarsal bones of the ankle and the sesamoid bone of the kneecap. Long bones such as the clavicle, that have a differently shaped shaft or ends are also called modified long bones. Short bones are roughly cube-shaped, and have only a thin layer of compact bone surrounding a spongy interior. Short bones provide stability and support as well as some limited motion. The bones of the wrist and ankle are short bones. Flat bones are thin and generally curved, with two parallel layers of compact bone sandwiching a layer of spongy bone. Most of the bones of the skull are flat bones, as is the sternum. Sesamoid bones are bones embedded in tendons. Since they act to hold the tendon further away from the joint, the angle of the tendon is increased and thus the leverage of the muscle is increased. Examples of sesamoid bones are the patella and the pisiform. Irregular bones do not fit into the above categories. They consist of thin layers of compact bone surrounding a spongy interior. As implied by the name, their shapes are irregular and complicated.
=== HANAC syndrome === Mutations in COL4A1 exons 24 and 25 are associated with HANAC (autosomal dominant hereditary angiopathy with nephropathy, aneurysms, and muscle cramps). It has also been confirmed that mutations in the COL4A1 gene occur in some patients with porencephaly and schizencephaly.
Sources: en.wikipedia.org
== Formation == The creation process of type I collagen begins with the production and the combination of two separate subunits, called the pro-alpha1(I) and pro-alpha2(I) chains. These pro-alpha chains are encoded by the COL1A1 and COL1A2 genes respectively and when combined produce type I pro-collagen. This transcriptional process takes place within the cell's endoplasmic reticulum and must undergo post-translational modifications in order to make the final type I collagen product. The procollagen complex is then modified by different enzyme proteinases which cleave N and C terminal pro-peptides that are present on either side of the molecule. This process occurs outside of the cellular membrane at which post processing, the molecules cross link and form a final type I collagen product.
The crystal lattices of solid americium and its compounds contain small intrinsic radiogenic defects due to metamictization induced by self-irradiation with alpha particles. These defects accumulate with time, which can cause a drift of some material properties and is more noticeable in older samples.
This was confirmed by another meta-analysis involving 945 286 patients in 8 retrospective cohort studies, most in the US. In 2012, the U.S. Justice Department announced GlaxoSmithKline had agreed to plead guilty and pay a $3 billion fine, in part for withholding the results of two studies of the cardiovascular safety of Avandia between 2001 and 2007.
In January 2018, after North Korea's leader Kim Jong Un and Trump publicly exchanged claims about their respective "nuclear buttons", Richard Painter, a former adviser to President George W. Bush, deemed Trump "psychologically unfit" and supported transferring his powers to Vice President Mike Pence under the 25th Amendment. In April 2018, Vanity Fair reported that Trump's advisers "worry about his mental health" when he is outside the controls available in the White House environment. In response to speculation about his cognitive abilities, Trump voluntarily took the Montreal Cognitive Assessment (MoCA) as part of his January 2018 health checkup. He reported receiving a score of 30/30, indicating a normal level of cognitive function, although the results have not been released. Critics have contended that the MoCA test is too basic to diagnose the problems asserted. Trump used the phrase "person, woman, man, camera, TV" several times during a July 2020 Fox News interview with Marc Siegel, a professor of medicine at New York University, while describing part of the 2018 MoCA test and praising his own performance on it. Trump has not publicly revealed the results of any subsequent cognitive tests but, as late as 2024, continued to praise his performance in the 2018 cognitive test. Ziad Nasreddine, the neurologist who created the test, noted that 2018 results would be too outdated to be relevant in 2024.
In July 2016 a post in CardiBrief called out several sales practices of True Health as examples of "a wide variety of new scams to gain new business...that emerged in the wake of the collapse and bankruptcy of Health Diagnostics Laboratory." These practices included setting up labs that would be majority-owned by the testing company and minority-owned by individual doctors. Those doctors could then financially benefit without owning the lab to send tests, which would be illegal; another was offering management services through blood-drawing service providers. In December 2016 the company started offering hospitals and medical practices laboratory management services. In April 2017 True Health started offering genetic testing to determine a person's risk for developing hereditary cancers. In July 2019 True Health Diagnostics filed for Chapter 11 Bankruptcy. According to filings, the company will be laying off about 80 employees. On August 23, 2019, the company filed a Notice of Sale of Property Free and Clear of Liens. No stalking horse bidder has been identified.
Sources: en.wikipedia.org
BioDuro provides end-to-end CRDMO services spanning early discovery through clinical development. Rather than list individual assays or sub-services, the company groups its offerings into several major business units.
Jerome Gross (February 25, 1917 - January 27, 2014) was an American biologist and member of the National Academy of Sciences. His research at Harvard Medical School and the Massachusetts General Hospital in the 1950s helped launch the fields of collagen research. In 1969, Gross was promoted to Professor of Medicine at Harvard Medical School and named Biologist at the Massachusetts General Hospital. In the preceding decades, scientists from around the world traveled to his Developmental Biology Laboratory in the Department of Medicine at the Massachusetts General Hospital to study his work on collagen structure, wound healing, and limb regeneration. In 1987, Gross became Professor Emeritus of Medicine at Harvard Medical School. The following year, he became the first Paul Klemperer Award recipient at the New York Academy of Medicine. In 1995 he was awarded the Lifetime Achievement Award by The Wound Healing Society. Gross spent over 60 years on the faculty of Harvard and in the labs of Mass General Hospital. He died one month shy of his 97th birthday in Waban, Massachusetts, of natural causes.
Dogs, the first domesticated animal, have been used in hunting, in security and in warfare, as have horses, pigeons and birds of prey; while other terrestrial and aquatic animals are hunted for sports, trophies or profits. Non-human animals are also an important element of human culture, having appeared in cave arts and totems since the earliest times, and are frequently featured in mythology, religion, arts, literature, heraldry, politics, and sports.
204Pb(48Ca,xn)252−xNo (x=2,3) The measurement of the 2n excitation function for this reaction was reported in 2001 by Yuri Oganessian at the FLNR. They reported a new isotope 250No with a half-life of 36 μs. The reaction was used in 2003 to study the spectroscopy of 250No.They were able to observe two spontaneous fission activities with half-lives of 5.6 μs and 54 μs and assigned to 250No and 249No, respectively. The latter activity was later assigned to a K-isomer in 250No. The reaction was reported in 2006 by Peterson et al. at the Argonne National Laboratory (ANL) in a study of SF in 250No. They detected two activities with half-lives of 3.7 μs and 43 μs and both assigned to 250No, the latter associated with a K-isomer. In 2020, a team at FLNR repeated this reaction and found a new 9.1-MeV alpha particle activity correlated to 245Fm and 241Cf, which they assigned to the new isotope 249No.
==== Phase I ==== The clinical trial Phase I began on 15-16 August at Hanoi Medical University. Phase I was conducted on 100 healthy volunteers randomly assigned in a ratio of 3:1, i.e. 75% of them received the ARCT-154 vaccine and 25% received a placebo. The primary objective of the phase one trial was to assess safety and immunogenicity of the vaccine. Volunteers will receive 2 doses of ARCT-154 vaccine or placebo, 28 days apart. Data of the volunteers from the first dose (day 1) to 7 days after the second dose (day 36), will be evaluated by the research team. Phase I report on the safety of the ARCT-154 vaccine was approved by the Ethics Committee on 20 September 2021. Preliminary results show that the ARCT-154 vaccine is safe in healthy volunteers.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.